CA 125, CA19-9 and CEA: tumor markers in bladder cancer

Siamak Daneshmand, MD, Keck School of Medicine, Los Angeles, CA, discusses the role of CA 125, CA19-9 and CEA in predicting patient outcomes following neoadjuvant chemotherapy in muscle-invasive bladder cancer (MIBC) at ASCO GU 2021. The study found that elevated serum levels of these tumor markers prior to neoadjuvant chemotherapy was associated with upstaging of disease and was associated with worse outcomes. The study also indicated that these tumor markers may be utilized for earlier detection of recurrence, post-cystectomy. This interview took place during the 2021 Genitourinary Cancers Symposium.